Search results
Results from the WOW.Com Content Network
VIVUS' (NAS: VVUS) stock was down 25% for November, though still up 15% for the year. Its drug Qsymia is the first obesity drug to be approved and reach the market in more than a decade, but its ...
For premium support please call: 800-290-4726 more ways to reach us
We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic ...
VIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of $0.56 per share on Monday, but this was not an earnings story. VIVUS remains a developing story about its obesity drug Qsymia. Its revenue ...
For premium support please call: 800-290-4726 more ways to reach us
The three main players in the obesity drug space -- VIVUS (NAS: VVUS) , Arena Pharmaceuticals (NAS: ARNA) , and Orexigen Therapeutics (NAS: OREX) -- are prepared to brave the market's reaction and ...
AP Images; Bridgeman Art Library: California Digital Library: California State University, Northridge, Oviatt Library Digital Collections Camera Press: Chicago Daily News (1902–1933), collection of over 55,000 images on glass plate negatives Corbis Images: Depositphotos: Stock Images: 164,000,000+ (June 2020) Yes No Yes English (Default)+ 21 ...
For premium support please call: 800-290-4726 more ways to reach us